^
Association details:
| Biomarker: | FGFR fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) + cetrelimab (JNJ-63723283) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Published date:
09/13/2021
Excerpt:
NORSE Ph 2 is enrolling pts ≥ 18 y with mUC, select FGFRa (mutation/fusion)...Efficacy data in response-evaluable pts are shown in the table....RDA + CET showed clinically meaningful responses in cis-ineligible patients with 1L mUC and FGFRa.
Trial ID:
